Relevance of Serum Levels of Interleukin-6 and Syndecan-1 in Patients with Hepatocellular Carcinoma
Open Access
- 1 January 2012
- journal article
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 80 (1), 179-188
- https://doi.org/10.3797/scipharm.1110-07
Abstract
Syndecan-1 is a trans-membrane heparan sulfate proteoglycan that localizes in epithelial cells and has been shown to be present in normal hepatocytes. It is thought to be involved in processes such as cell growth, differentiation and adhesion. However, the clinical data regarding syndecan-1 in patients with hepatocellular carcinoma (HCC) are scarce and controversial. Therefore, we need to evaluate the effects of HCC on the serum levels of syndecan-1. Thus, 40 patients with HCC and 31 patients with liver cirrhosis were physically examined. Blood samples were taken for measurements of routine markers (sGPT, sGOT, bilirubin, albumin, and α-fetoprotein), as well as serum levels of interleukin (IL)-6 and syndecan-1. Patients with liver cirrhosis showed significant increase in serum IL-6 as compared with HCC patients and the control subjects. Serum level of syndecan-1 was significantly increased in HCC patients as compared with the cirrhotic and control groups. In addition, significant positive correlations between syndecan-1 and serum levels of ALT, AST in HCC patients were found. Moreover, syndecan-1 increased significantly with increasing stage of Barcelona-Clinic Liver Cancer Group diagnostic and treatment strategy. In conclusion, the development of HCC is accompanied by a significant elevation in serum syndecan-1 levels. The increase in serum syndecan-1 may be linked with progression of HCC.This publication has 26 references indexed in Scilit:
- Circulating interleukin-6 as a tumor marker for hepatocellular carcinomaAnnals of Oncology, 2007
- Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaBlood, 2007
- Heparanase Enhances Syndecan-1 SheddingOnline Journal of Public Health Informatics, 2007
- Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinomaEuropean Journal of Surgical Oncology, 2007
- An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situBreast Cancer Research, 2007
- The Levels of Ghrelin, Leptin, TNF-α, and IL-6 in Liver Cirrhosis and Hepatocellular Carcinoma due to HBV and HDV InfectionMediators of Inflammation, 2006
- Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinomaWorld Journal of Gastroenterology, 2006
- Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinomaWorld Journal of Gastroenterology, 2006
- Growth factor–induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cellsThe Journal of cell biology, 2005
- Enhanced Detection of Hepatocellular CarcinomaCancer Control, 2005